Two Sigma Investments LP Sells 126,870 Shares of Hologic, Inc. (NASDAQ:HOLX)

Two Sigma Investments LP reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 56.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,784 shares of the medical equipment provider's stock after selling 126,870 shares during the quarter. Two Sigma Investments LP's holdings in Hologic were worth $7,049,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of HOLX. Venturi Wealth Management LLC lifted its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the period. Smithfield Trust Co increased its stake in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in Hologic during the 4th quarter valued at about $49,000. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the topic of a number of recent research reports. Stephens cut their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. William Blair restated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Raymond James reiterated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Citigroup decreased their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus price target of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Price Performance

Shares of HOLX traded down $0.62 during trading hours on Friday, reaching $62.30. 562,406 shares of the stock traded hands, compared to its average volume of 2,247,836. The company has a market cap of $13.88 billion, a P/E ratio of 19.70, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company's 50-day moving average price is $58.11 and its two-hundred day moving average price is $66.10. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business's revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.03 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.